General Information About Financial Statements [Line Items]

No definition available.

Name:	cntg_GeneralInformationAboutFinancialStatementsLineItems
Namespace Prefix:	cntg_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	cntg_IfrsSharePrice
Namespace Prefix:	cntg_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

No definition available.

+ Details

Name:	cntg_IfrsStockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	cntg_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 55
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash inflow from borrowings obtained. [Refer: Borrowings]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 17
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 17
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ProceedsFromIssueOfOrdinaryShares
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2023-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2023-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInJointVenture
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_JointVenturesAxis=cntg_GenomicsInnovationsCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfFinancialLiabilitiesAxis=cntg_ConvertibleLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cntg_PharmaceuticalInvestmentCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

General company information (Details) € / shares in Units, $ / shares in Units, € in Thousands, $ in Millions				12 Months Ended
	Oct. 30, 2023 USD ($)	Jun. 26, 2023 EUR (€)	Jan. 31, 2022 EUR (€) shares	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Jun. 26, 2023 SAR (ر.س)	Jan. 31, 2022 $ / shares	Jan. 31, 2022 € / shares
General company information
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs			€ 15,000
Number of common shares issued (in shares) \| shares			4,479,088
Share price \| (per share)								$ 3.73	€ 3.35
Investment in Joint Venture				€ 2,784
Cash received from loans				€ 25,500	€ 40,568	€ 1,772
Genomics Innovations Company Limited
General company information
Proportion of ownership interest in joint venture		20.00%		20.00%
Investment in Joint Venture		€ 4,973		€ 2,784			ر.س 20,000,000
Genomics Innovations Company Limited \| Convertible Loan
General company information
Cash received from loans \| $	$ 30
Major ordinary share transactions
General company information
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs			€ 15,000
Number of common shares issued (in shares) \| shares			4,479,088
Share price \| $ / shares								$ 3.73
Pharmaceutical Investment Company \| Genomics Innovations Company Limited
General company information
Proportion of ownership interest in joint venture		80.00%
Investment in Joint Venture		€ 19,892					ر.س 80,000,000